Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma reported a year-end net loss of $18.86M for FY2026, improved from a $58.92M loss in FY2025, with zero | Sep 29, 2026 |
| LITS | PRESS-RELEASE | neutral | 5/10 | Lite Strategy reported FY2026 results, its first full year operating under a Litecoin (LTC) treasury strategy. The compa | Sep 29, 2026 |
| VOR | PRESS-RELEASE | bullish | 6/10 | Vor Bio announced positive post hoc Phase 3 data for telitacicept in generalized myasthenia gravis, showing >94% of part | Sep 29, 2026 |
| SLXN | PRESS-RELEASE | bearish | 6/10 | Silexion Therapeutics entered into definitive agreements for the immediate cash exercise of outstanding Series E warrant | Sep 29, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings subsidiary NorthStrive Biosciences engaged Charles River Laboratories for analytical characterization work | Sep 29, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology and Caspian Therapeutics announced preclinical data for KO-7246, a menin inhibitor for diabetes, showing β | Sep 29, 2026 |
| PHAR | PRESS-RELEASE | bearish | 6/10 | Pharming Group announced that CEO Fabrice Chouraqui has stepped down immediately by mutual agreement with the Board due | Sep 29, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | AstraZeneca submitted an NDA to the FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-overexpressed/ampl | Sep 28, 2026 |
| NAII | PRESS-RELEASE | bearish | 6/10 | NAI reported Q4 FY2026 net sales of $34.5M (+1.9% YoY) but a net loss of $13.5M ($2.23/diluted share), including a $10.4 | Sep 28, 2026 |
| ATTO | PRESS-RELEASE | neutral | 3/10 | Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline at | Sep 28, 2026 |
| TEVA | PRESS-RELEASE | bullish | 7/10 | Teva announced FDA approval of DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab) for preventing bone complic | Sep 28, 2026 |
| LFCR | PRESS-RELEASE | bullish | 7/10 | Lifecore Biomedical announced it will be acquired by Webster Equity Partners in a take-private transaction. The deal pro | Sep 28, 2026 |
| SLXN | PRESS-RELEASE | neutral | 3/10 | Silexion Therapeutics announced translational research data showing its SIL204 candidate leverages native serum lipids f | Sep 28, 2026 |
| KROS | PRESS-RELEASE | neutral | 3/10 | Keros Therapeutics announced the first patient dosed in a Phase 2 clinical trial of rinvatercept for Duchenne muscular d | Sep 28, 2026 |
| ALXO | PRESS-RELEASE | mixed | 5/10 | ALX Oncology published Phase 2 ASPEN-06 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs 26.6% | Sep 28, 2026 |
| ALLR | PRESS-RELEASE | neutral | 3/10 | Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line res | Sep 28, 2026 |
| IMRX | PRESS-RELEASE | bullish | 6/10 | Immuneering presented exploratory Phase 2a data at AACR Pancreatic Cancer 2026 showing that pancreatic cancer patients o | Sep 28, 2026 |
| SCYX | PRESS-RELEASE | bullish | 6/10 | SCYNEXIS announced a BARDA contract worth up to ~$214M (if all options exercised) to fund development of SCY-247, its se | Sep 28, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber filed an 8-K/A providing audited financials for its Bridgeport manufacturing acquisition, confirming a $4. | Sep 28, 2026 |
| PBM | PRESS-RELEASE | neutral | 4/10 | Psyence Biomedical subsidiary Texas Ibogaine Research Corporation (TIRC) signed a binding term sheet with related-party | Sep 28, 2026 |
| BLSM | PRESS-RELEASE | bearish | 7/10 | BlossomHill Therapeutics reported Q2 2026 EPS of -$8.75, a 874% miss vs consensus of -$0.90, with zero revenue. The comp | Sep 28, 2026 |
| MNOV | PRESS-RELEASE | mixed | 5/10 | MediciNova reported Phase 2 topline results for MN-001 (tipelukast) in hypertriglyceridemia and NAFLD with T2DM. The stu | Sep 28, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI (revefenacin) for a mid-teens base-case IRR. | Sep 28, 2026 |
| NGEN | PRESS-RELEASE | neutral | 4/10 | NervGen Pharma announced a non-cash restatement of its 2025 annual and Q2 2026 interim financial statements, revising th | Sep 25, 2026 |
| SLS | PRESS-RELEASE | neutral | 3/10 | SELLAS Life Sciences presented preclinical data at AACR showing its CDK9 inhibitor SLS009 induced substantially greater | Sep 25, 2026 |
| PHAR | PRESS-RELEASE | bullish | 5/10 | Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) in children age | Sep 25, 2026 |
| CDT | PRESS-RELEASE | bearish | 6/10 | CDT Equity announced a 1-for-25 reverse stock split effective September 28, 2026, to regain compliance with Nasdaq's bid | Sep 25, 2026 |
| ADPT | PRESS-RELEASE | bullish | 6/10 | Adaptive Biotechnologies announced a new consensus definition of cure for multiple myeloma, established by IMS and IMWG, | Sep 25, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber issued a press release reframing its strategic focus around three product pillars (one-way attack drones/i | Sep 25, 2026 |
| CCCC | PRESS-RELEASE | neutral | 4/10 | C4 Therapeutics presented biomarker data at IMS 2026 showing cemsidomide activates T cells and prevents exhaustion in RR | Sep 25, 2026 |